Subscribe
  
IPQ Inside the global regulatory dialogue

Relationship with Excipient Providers Drawing Increasing Pharma Attention, BMS Exec Stresses; IPEC Urges Regulatory Pathway for New Excipients in GDUFA/PDUFA Comments

Aug 29th, 2015

Please Log in to print the full article

An important component in the ability of pharmaceutical innovators to bring their new products to market in the eclipsed timelines in which they need to function will be their relationship with excipient providers, a top manufacturing executive from Bristol-Myers Squibb (BMS) stressed to participants at the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas)/ExcipientFest conference in San Juan, Puerto Rico in late April.

Providing the final keynote talk at the conference, BMS Pharmaceutical Operations Senior VP Ricardo Zayas made a compelling case for why this relationship has become increasingly important in pharmaceutical product development and to the financial viability of the companies involved. Zayas has responsibility for the strategic and operational leadership for BMS’ global supply chain.

Explaining that development to launch speed “is the single most important imperative right now” for an innovator company like BMS, Zayas stressed the need “now more than ever” to work with excipient suppliers “to reduce this.”

[The story continues for subscribers beginning on p. 2. Nonsubscribers can get information on IPQ subscriptions/licensing and individual story purchasing by contacting Wayne Rhodes ([email protected]).]

Pages: 1 2

    ©2020 IPQ Publications